C

    Candel Therapeutics Inc (CADL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.07
    -0.68 (-4.95%)

    Market Cap: $1.00B

    Last updated: Sep 01, 2026 at 4:59 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(9/20)
    Avg Surprise
    -6.85%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.31
    Range$-0.33 - $-0.29
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.26+16.1%
    30d ago$-0.25+19.4%
    7d ago$-0.25+19.4%
    Current$-0.31
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.13
    Range$-0.41 - $0.13
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.13---
    Sep 26EST
    		-$-0.31---
    Jun 26
    Reported Aug 13
    		$-0.35$-0.22-59.09%Miss-75.0%
    Mar 26
    Reported May 14
    		$-0.14N/A+57.58%Beat+0.0%
    Dec 25
    Reported Mar 12
    		$-0.29$-0.25-17.01%Miss+27.3%
    Sep 25
    Reported Nov 13
    		$-0.23$-0.16-43.75%Miss+30.3%
    Jun 25
    Reported Aug 14
    		$-0.20$-0.17-17.65%Miss+73.0%
    Mar 25
    Reported May 13
    		$-0.14$-0.24+41.67%Beat+50.3%
    Dec 24
    Reported Mar 13
    		$-0.40$-0.30-33.33%Miss-5.3%
    Sep 24
    Reported Nov 14
    		$-0.33N/AN/ABeat-13.8%
    Jun 24
    Reported Aug 13
    		$-0.74$0.00N/ABeat-124.2%
    Mar 24
    Reported May 14
    		$-0.28$-0.28-0.57%Miss+6.1%
    Dec 23
    Reported Mar 28
    		$-0.38$-0.16-137.50%Miss-111.1%
    Sep 23
    Reported Nov 9
    		$-0.29$-0.19-52.63%Miss+6.5%
    Jun 23
    Reported Aug 10
    		$-0.33$-0.37+10.81%Beat-3.1%
    Mar 23
    Reported May 11
    		$-0.30$-0.35+14.29%Beat+6.3%
    Dec 22
    Reported Mar 30
    		$-0.18$-0.31+41.94%Beat-158.1%
    Sep 22
    Reported Nov 10
    		$-0.31$-0.36+13.89%Beat+8.8%
    Jun 22
    Reported Aug 5
    		$-0.32$-0.43+25.58%Beat-3.2%
    Mar 22
    Reported May 12
    		$-0.32$-0.31-3.23%Miss+7.9%
    Dec 21
    Reported Mar 29
    		$0.31$-0.32+196.88%Beat-
    Sep 21
    Reported Nov 12
    		$-0.34$-0.29-17.24%Miss-
    Jun 21
    Reported Jul 28
    		$-0.31$-0.12-158.33%Miss-
    Mar 21
    Reported Jun 2
    		$-0.35$-0.35+0.74%Beat-

    Key Metrics

    Valuation
    P/E Ratio-12.93EV/EBITDA-0.01x
    Price/FCF-16.90xFCF Yield-5.92%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-81.80%ROIC-40.36%
    Financial Health
    Debt/Equity0.38xInterest Coverage-18.84x
    Current Ratio16.09xQuick Ratio16.09x
    Trading Statistics
    Beta-0.50Avg Volume1.26M
    52-Week High$14.0052-Week Low$4.35

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.97
    SMA 20$11.87
    SMA 50$10.58
    SMA 200$7.19
    EMA 10$12.85
    EMA 20$12.12
    EMA 50$10.77
    EMA 200$8.11

    MACD

    Line: 0.92Signal: 0.81Hist: 0.11

    ADX

    ADX: 46.2+DI: 30.3-DI: 7.1

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down12.0
    PSAR$12.85

    Bollinger Bands

    Upper Band$14.41
    Lower Band$9.32
    %B Position4286%(Upper)
    Band Width0.74

    RSI (14-Day)

    Neutral
    61.4

    Momentum Oscillators

    Stoch %K82.9
    Stoch %D84.2
    Williams %R-25.9
    ROC (10d)11.5%
    Momentum1.35
    CCI (20d)85.5
    MFI (14d)75.6

    Volatility Measures

    ATR (14d)$0.78(6.0%)
    StdDev (20d)1.27
    Hist Vol76.8%(High)

    Volume Flow

    VWAP$13.25
    OBV24.8M
    AD Line-14.0M
    CMF (20d)0.256

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.0x
    VWMA (20d)$12.05

    Pivot Points

    R3$14.90
    R2$14.45
    R1$14.10
    Pivot Point$13.65
    S1$13.30
    S2$12.85
    S3$12.50

    Advanced Oscillators

    TSI33.55
    Ultimate Osc52.1
    KST275.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1.00M$0$0$0$1.78M$0
    Cost of Revenue$0$0$163,000$0$0$0$245,000$0$0$0$312,000$0
    Gross Profit$0$0$-163,000$0$0$0$-245,000$0$0$0$1.46M$0
    Operating Expenses$26.75M$16.28M$15.75M$13.21M$11.18M$8.13M$8.14M$8.76M$8.57M$7.90M$10.32M$8.86M
    R&D$19.80M$9.84M$11.03M$8.46M$6.99M$4.02M$4.82M$5.42M$4.98M$4.10M$7.26M$5.84M
    SG&A$6.95M$6.44M$4.72M$4.75M$4.19M$4.11M$3.32M$3.34M$3.59M$3.80M$3.06M$3.02M
    Operating Income$-26,746,000$-16,284,000$-15,752,000$-13,207,000$-11,177,000$-8,130,000$-8,141,000$-8,757,000$-8,571,000$-7,902,000$-10,318,000$-8,861,000
    Interest Income$1.67M$1.32M$1.10M$953,000$926,000$934,000$290,000$236,000$240,000$320,000$415,000$502,000
    Interest Expense$1.57M$1.56M$1.42M$161,000$236,000$306,000$390,000$487,000$567,000$646,000$673,000$669,000
    Income Before Tax$-38,905,000$-8,861,000$-29,496,000$-11,269,000$-4,796,000$7.38M$-14,073,000$-10,646,000$-22,237,000$-8,221,000$-11,095,000$-8,435,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-38,905,000$-8,861,000$-29,496,000$-11,269,000$-4,796,000$7.38M$-14,073,000$-10,646,000$-22,237,000$-8,221,000$-11,095,000$-8,435,000
    EBITDA$-38,831,000$-8,470,000$-29,019,000$-11,866,000$-5,244,000$7.00M$-13,728,000$-10,150,000$-21,661,000$-7,644,000$-10,588,000$-8,023,000
    EBIT$-39,002,000$-8,619,000$-29,182,000$-12,061,000$-5,486,000$6.75M$-13,973,000$-10,395,000$-21,910,000$-7,895,000$-10,837,000$-8,268,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CADL

    News

    Candel Therapeutics stock hits 52-week high at $13.96

    Candel Therapeutics Inc.'s stock recently hit a 52-week high of $13.96, reflecting a 132.47% increase over the past year and strong investor confidence. The company is advancing its clinical pipeline, including a global Phase III trial for aglatimagene besadenovec, and has received positive analyst ratings and a new Chief Commercial Officer appointment, further highlighting its growing presence in the biotechnology sector.

    Investing.com•8/27/26•
    Bullish

    Has Candel Therapeutics (CADL) Run Too Far Ahead On Widening Losses?

    Candel Therapeutics (CADL) reported widening net losses of US$38.91 million in Q2 2026, yet its stock has seen significant gains, up 37.34% in one month and 141.36% year-to-date. Despite trading at a price-to-book ratio of 8x, well above industry averages, and showing increasing losses, an SWS Discounted Cash Flow model suggests a large undervaluation. This discrepancy highlights investor focus on its pipeline and future potential, despite current unprofitability and risks associated with unproven clinical programs.

    Simply Wall Street•8/24/26•
    Somewhat-Bearish

    Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey

    Candel Therapeutics (CADL) reported a significant increase in net losses to US$38.91 million in Q2 2026, up from US$4.8 million a year prior, despite a sharp rise in share price. The company's valuation, with a Price-to-Book ratio of 8.2x, appears pricey compared to industry averages, reflecting investor confidence in its development pipeline rather than current earnings. While the P/B ratio suggests overvaluation, a Discounted Cash Flow model indicates a large potential upside, highlighting conflicting valuation signals for the clinical-stage biopharmaceutical company.

    Yahoo Finance•8/20/26•
    Somewhat-Bearish

    Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed?

    Candel Therapeutics (CADL) reported a significant widening of its net loss to US$38.91 million in Q2 2026, with first-half losses reaching US$47.77 million, marking a sharp shift from prior-year profitability. This increased cash burn raises concerns about funding and potential shareholder dilution, despite promising clinical catalysts like the planned prostate cancer BLA filing. While shares are up, the company's need for capital to advance its late-stage programs will be a key factor for investors.

    Simply Wall Street•8/20/26•
    Somewhat-Bearish

    Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed?

    Candel Therapeutics (CADL) saw its net loss widen significantly in Q2 2026 to US$38.91 million, with first-half losses reaching US$47.77 million, marking a sharp shift from prior-year profitability. Despite a 26.4% share price increase, this financial performance raises concerns about funding and potential dilution, even as the company progresses with clinical trials for its CAN-2409 platform. Investor opinions on the stock's fair value vary widely, reflecting a divide between optimism for late-stage catalysts and worries about cash burn.

    Simply Wall Street•8/20/26•
    Bearish

    Frequently Asked Questions About CADL

    Does CADL pay dividends?
    Candel Therapeutics Inc (CADL) does not currently pay a regular dividend.
    What is CADL's market cap?
    Candel Therapeutics Inc (CADL) has a market capitalization of $1.00B with a current stock price of $13.07.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In